NuVasive commemorates industry-defining innovation in the
lateral procedural segment
SAN
DIEGO, March 13, 2023 /PRNewswire/
-- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine
technology innovation, focused on transforming spine surgery with
minimally disruptive, procedurally integrated solutions, announced
today the 20-year milestone achievement of its lateral lumbar
procedure, extreme lateral interbody fusion (XLIF).
"20 years ago, we set out to make spine surgery more
reproducible and improve patient outcomes through the development
and introduction of the XLIF procedure," said Ryan Donahoe, chief technology officer at
NuVasive. "Through our leadership in outcome-driven design,
partnership with the best spine clinicians around the globe, and a
continued focus on clinical education and validation, we have
learned that it is foundational to approach innovation across the
full continuum of spine care."
"It's been quite a journey since I started working with NuVasive
in 2001, being attracted to the vision of making spine surgery
better. In collaboration with a handful of my peers and the
NuVasive team, creating the XLIF procedure was a decision that
stemmed from us realizing that the outcomes we were seeing weren't
good enough," said Dr. Frank
Phillips, director of the division of spine surgery at
Rush University Medical Center. "This
proven innovation is an incredible example of how thoughtful
procedural design and reliable, reproducible clinical results can
improve the overall care experience."
Today, with ~300,000 procedures performed, 200+ educational
courses hosted, 500+ peer-reviewed publications and 60+ products
launched, XLIF continues to demonstrate superior and more
predictable outcomes than traditional spinal fusion
procedures.1-4 Specifically designed to treat
pathologies effectively and reproducibly at levels L4-L5 and above,
XLIF has been proven to reduce operative time, incision size, blood
loss during surgery, length of hospital stay, postoperative pain,
and postoperative recovery time.1-4
"Over the years, I've seen XLIF take over the lateral market,
making less-invasive spine surgery more reproducible," said Dr.
Paul Holman, chief of spinal
neurosurgery at Houston Methodist. "When paired with the
enabling technologies within Pulse, XLIF unlocks even more clinical
value for both the surgeon and the patient."
Building on the legacy of XLIF, the Company has since launched
its X360, P360, C360 and Complex procedural portfolios. The next
phase of NuVasive innovation is intelligent surgery. From planning
to execution to postoperative data, intelligent surgery will
proliferate each portfolio to provide better patient, surgeon and
hospital outcomes.
"The concept of intelligent surgery will take what we know of
XLIF and more recently with X360, to greater heights," said
Alex Thomas, neurosurgeon at
Atlantic Brain and Spine. "I'm excited to see how we can leverage
the power of data to make better decisions preoperatively and
intraoperatively, and then track our outcomes more intelligently,
postoperatively."
- Sembrano JN, Tohmeh A, Isaacs R, et al. Two-year comparative
outcomes of MIS lateral and MIS transforaminal interbody fusion in
the treatment of degenerative spondylolisthesis: part I: clinical
findings. Spine 2016;41(Suppl 8):S123-32.
- Lehmen JA, Gerber EJ. MIS lateral spine surgery: A systematic
literature review of complications, outcomes, and economics. Eur
Spine J 2015;24(Suppl 3):287-313.
- Rihn JA, Patel R, Makda J, et al. Complications associated with
single-level transforaminal lumbar interbody fusion. Spine J
2009;9(8):623-9.
- Lucio JC, VanConia RB, Deluzio KJ, et al. Economics of less
invasive spinal surgery: an analysis of hospital cost differences
between open and minimally invasive instrumented spinal fusion
procedures during the perioperative period. Risk Management and
Healthcare Policy 2012;5:65-74.
About NuVasive
NuVasive,
Inc. (NASDAQ: NUVA) is the leader in spine technology
innovation, with a mission to transform surgery, advance care, and
change lives. The Company's less-invasive, procedurally integrated
surgical solutions are designed to deliver reproducible and
clinically proven outcomes. The Company's comprehensive procedural
portfolio includes surgical access instruments, spinal implants,
fixation systems, biologics, software for surgical planning,
navigation and imaging solutions, magnetically adjustable implant
systems for spine and orthopedics, and intraoperative
neuromonitoring technology and service offerings. With more
than $1 billion in net sales, NuVasive operates
in more than 50 countries serving surgeons, hospitals, and
patients. For more information, please
visit www.nuvasive.com.
Forward-Looking
Statements
NuVasive cautions you that statements
included in this news release that are not a description of
historical facts are forward-looking statements that involve risks,
uncertainties, assumptions and other factors which, if they do not
materialize or prove correct, could
cause NuVasive's results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties
which contribute to the uncertain nature of these statements
include, among others, risks associated with acceptance of the
Company's surgical products and procedures by spine surgeons and
hospitals, development and acceptance of new products or product
enhancements, clinical and statistical verification of the benefits
achieved via the use of NuVasive's products, the
Company's ability to adequately manage inventory as it continues to
release new products, its ability to recruit and retain management
and key personnel, and the other risks and uncertainties described
in NuVasive's news releases and periodic filings with
the Securities and Exchange
Commission. NuVasive's public filings with
the Securities and Exchange Commission are available at
www.sec.gov. NuVasive assumes no obligation to update any
forward-looking statement to reflect events or circumstances
arising after the date on which it was made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvasive-celebrates-20-year-milestone-of-the-xlif-procedure-301769454.html
SOURCE NuVasive, Inc.